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Laboratory confirmation of paediatric tuberculosis 
(TB) is frequently lacking. We reviewed the range of 
routine laboratory tests and their performance in dif-
ferent biological samples used to diagnose active TB 
in children. A questionnaire-based survey was con-
ducted among the European Reference Laboratory 
Network for TB followed by collection of routine lab-
oratory data on 10,549 paediatric samples tested in 
2007 to 2011 at six reference laboratories (in Croatia, 
Germany, Italy, Latvia, Lithuania and the United 
Kingdom (UK)). The questionnaire showed that all 
laboratories used rapid assays. Non-respiratory sam-
ples were collected more often in Germany (135/275, 
49.1%) and the UK (490/2,140, 22.9%) compared with 
Croatia (138/2,792, 4.9%), Latvia (222/2,401, 9.2%) 
and Lithuania (76/1,549, 4.9%). Overall laboratory 
positivity rates (isolation of Mycobacterium tuberculo-
sis complex and/or identification of its nucleic acids in 
a sample) were higher in lymph node and gastric aspi-
rate samples (14/203 (6.9%) and 43/1,231 (3.5%)) than 
in sputum samples (89/4,684 (1.9%)). Pooled sensitiv-
ity, specificity, positive and negative predictive values 
and accuracy of molecular assays assessed against 
solid or liquid culture were 79.2%, 93.6%, 67.1%, 
96.5% and 91.6%, respectively. A more intensive 
approach in obtaining gastric aspirate and non-respir-
atory samples may increase laboratory confirmation of 
paediatric TB. Major effort is needed in optimisation 
and validation of molecular tests in these samples.
Introduction
Tuberculosis (TB) affects globally about 490,000 chil-
dren under 15 years-old, with 64,000 related deaths 
occurring every year [1]. Paediatric TB is an indicator 
of recent transmission in the population. Often, chil-
dren experience more severe forms of the disease, 
such as miliary or meningeal TB [2,3]. Young  children 
are rarely able to expectorate sputum; therefore, other 
respiratory samples, such as gastric aspirates (GA) or 
bronchoalveolar lavages (BAL), can be obtained for 
diagnostic purposes, although these procedures are 
more unpleasant for a child  than sputum collection 
[1,3-5]. Collection of non-respiratory samples (lymph 
node (LN), pus or tissue biopsy) is necessary to diag-
nose extrapulmonary TB; however, these procedures 
are relatively invasive [6,7].
TB in children often has a paucibacillar nature, result-
ing in microscopy smears that are negative [3,4,8]. 
Culture isolation, a more sensitive method, takes up to 
14 days due to slow growth of Mycobacterium tubercu-
losis complex (MTB(C)) bacteria; however, even culture 
is seldom positive in paediatric specimens due to very 
few bacilli present in a sample [3,4,8]. Further full drug 
susceptibility testing (DST) can only be done once an 
isolate is available and takes two more weeks [9,10].
Consequently, the diagnosis of paediatric TB often 
relies on a combination of clinical judgment and radi-
ological findings, prompting initiation of treatment 
without clear laboratory evidence [1,8,9,11,12]. Unlike 
laboratory criteria, there is as yet no universally applied 
diagnostic algorithm based on clinical and radiological 
criteria that are objective [8,11,12].
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The most important advance in TB diagnosis is the 
introduction of the internationally endorsed molecu-
lar assay Xpert MTB/RIF (Cepheid Inc., Sunnyvale, CA, 
United States), which identifies MTB and rifampicin 
resistance from sputum samples [13]. A growing body 
of evidence supports the adequacy of Xpert MTB/RIF 
for adult TB diagnosis [14-16].
Recent studies have investigated the performance 
of the Xpert MTB/RIF system in children and showed 
promising results when the test is applied to sputum, 
nasopharyngeal aspirates (NPA), GA or non-respiratory 
samples [4,6,7,17-19]. However, there are limited data 
on the usefulness of molecular assays for paediatric TB 
diagnosis in Europe, where TB prevalence is low [20].
The aim of the study was to give an overview of the 
range of routine diagnostic tests and their performance 
for different types of samples used to diagnose active 
TB in children across European laboratories.
Methods
Study design 
The study was planned in two stages. Firstly, we 
invited all (38) national TB reference laboratories 
across the European Union (EU)/European Economic 
Area (EEA) countries that are members of the European 
Reference Laboratory Network for TB (ERLN-TB) – an 
initiative supported by the European Centre for Disease 
Prevention and Control (ECDC) [21] – to participate in a 
questionnaire-based survey. The questionnaire aimed 
to determine the variety of algorithms used to diagnose 
paediatric TB and the type of samples collected from 
children; it contained 53 questions and was based on 
an earlier questionnaire used across the ERLN-TB [22].
Secondly, six laboratories of the network (referred to 
hereafter as study sites) agreed to provide their routine 
data for all consecutive primary samples and reference 
cultures referred for diagnosis from children younger 
than 15 years-old with suspected TB during 2007 to 
2011.
Primary samples were defined as specimens referred 
to a reference laboratory for primary diagnostics, while 
reference cultures were cultures isolated by local labo-
ratories and referred to a reference laboratory for con-
firmation, DST or molecular typing.
Low-incidence western and central European set-
tings were represented by the following laborato-
ries: the National Reference Centre for Mycobacteria 
at Forschungszentrum Borstel, Borstel, Germany; 
San Raffaele Scientific Institute, in collaboration 
with the Institute ‘Villa Marelli’, Niguarda Ca´ Granda 
Hospital, Milan, Italy; the National Mycobacterium 
Reference Laboratory, Public Health England, London, 
United Kingdom (UK) and the National Mycobacterium 
Reference Laboratory, National Institute of Public 
Health, Zagreb, Croatia (TB incidence in 2012  being 
5.6, 6.7, 15.0 and 14.0 cases per 100,000 population in 
the respective countries [23]). 
The National TB Reference Laboratory at the Latvian 
Infectology Centre, Upeslejas, Latvia, and the 
Tuberculosis Bacteriology Laboratory at the Infectious 
Diseases and Tuberculosis Hospital, Vilnius, Lithuania, 
represented medium-incidence eastern European coun-
tries, with TB incidence in 2012 being 53.0 and 66.0 
cases per 100,000 population, respectively [23].
Only partial data were available from the Italian site for 
2011; this is the only site that does not have a national 
reference laboratory function, covering mainly the 
Lombardy region of Italy. Germany provided data for 
2011 only. We did not exclude control samples, as there 
were only a few of those.
The laboratory data were collected using an Excel-
based tool, with line-listing by sample. The Croatian, 
German, Italian and UK sites received a small propor-
tion of all paediatric samples in the country (estimated 
by the laboratory directors as less than 10%), while 
the Lithuanian site covered approximately half and the 
Latvian site all paediatric samples in their countries.
Laboratory positivity was confirmed by a positive cul-
ture (on solid or liquid media) identified as MTB(C) or 
non-tuberculous mycobacteria (NTM) and/or by the 
identification of MTB(C) or NTM nucleic acid directly in 
a sample by a molecular assay.
Ethics statement
Routine laboratory data were sent to the Robert Koch 
Institute, Berlin, Germany, without personal identifi-
ers. The study obtained a waiver of informed consent 
and ethics review permission from the Robert Koch 
Institute.
Data analysis
Per-sample and per-patient analyses were conducted. 
Samples were categorised as ‘respiratory’ (sputum, 
BAL, GA, pleural fluid and other respiratory samples 
such as NPA), ‘non-respiratory’ (cerebrospinal fluid 
(CSF), LN, pus, blood, other tissue biopsy, urine and 
other non-respiratory samples such as pericardial 
fluid) and ‘unknown’ (where exact information on sam-
ple type was missing from the records).
Calculations related to the MTB(C) did not include 
the Mycobacterium bovis strain used in the Bacillus 
Calmette–Guérin (BCG) vaccine. 
The incremental positivity rate, defined as additional 
sensitivity gained by testing more than one sample 
from the same patient, was calculated for GA samples.
Associations between correct diagnostic yield and 
sample type were tested using Pearson’s chi-squared 
test or Fisher’s exact test. Statistical tests were two-
sided at alpha=0.05.
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The results of the different types of molecular tests 
were pooled since the number of samples did not allow 
stratified analysis of each test. Sensitivity, specificity, 
positive and negative predictive values (PPV and NPV, 
respectively) and the accuracy of the pooled molecular 
assays was assessed against culture and DST results 
in samples tested by both methods.
The answers from the survey questionnaire were 
entered into EpiData (EpiData Association, Odense, 
Denmark) and analysed using STATA (StataCorp. 2011. 
Stata Statistical Software: Release 12. College Station, 
TX: StataCorp LP). The routine laboratory data were 
collected from the study sites using a Microsoft Excel 
spreadsheet and analysed in STATA.
Results
Questionnaire-based survey
A total of 21 TB reference laboratories from Belgium, 
Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, 
Finland, Germany, Greece, Hungary, Italy (two labora-
tories), Latvia, Lithuania, Norway, Portugal, Slovenia, 
Spain (two laboratories), Sweden and the UK sent their 
responses.
The population served by these laboratories var-
ied between 400,000 and 20,000,000 inhabitants. 
Annually, the laboratories receive a median of 70 
(range: 6–950) paediatric primary samples and refer-
ence cultures representing a median of 3.1% (range: 
0.3–8.3%) of the total laboratory workload.
Of the 21 laboratories, 16 receive primary samples; the 
Latvian and Lithuanian laboratories receive primary 
samples only. Five laboratories receive reference cul-
tures only (Belgium, Czech Republic, Finland, Norway 
and Spain). The most common sample type received 
from children is sputum (16 laboratories), followed by 
GA and BAL (15 laboratories each). A total of 11 labora-
tories reported receiving more than one type of sample 
from each child.
All laboratories receiving primary samples perform 
smear microscopy, molecular identification, culture 
(solid or liquid media, commercial or in-house) and first- 
and second-line DST. All undergo international quality 
assurance, demonstrating satisfactory performance. 
The most frequently used direct rapid molecular 
identification assay included Xpert MTB/RIF (n=10) 
and GenoType MTBDRplus (Hain Lifescience, GmbH, 
Germany) (n=8); 10 laboratories used more than 
one assay. All laboratories rapidly identified MTB(C) 
from positive culture using GenoType CM/AS (Hain 
Lifescience, GmbH, Germany) (n=11), BD MGIT TBc 
Id (Becton Dickinson, United States) and GenoType 
MTBDRplus assays (n=8 each). Nine laboratories 
Table 1
Laboratory diagnosis of paediatric tuberculosis: types of paediatric primary samples received across the six study sites, 
2007–2011 (n=9,157)









CIPH 2,792 2,650 (94.9) 138 (4.9) 4 (0.1)
Germanyb 
NRCM 275 129 (46.9) 135 (49.1) 11 (4.0)
Italyb 
HSR 340 NA NA NA
Latvia 
NTRL 2,401 2,167 (90.3) 222 (9.2) 12 (0.5)
Lithuania 
TBL 1,549 1,464 (94.5) 76 (4.9) 9 (0.6)
United Kingdom 
NMRL 2,140 1,643 (76.8) 490 (22.9) 7 (0.3)
All sites 9,157c 8,053 (87.9) 1,061 (11.6) 43 (0.5)
CIPH: Croatian National Institute of Public Health, National Mycobacterium Reference Laboratory; HSR: San Raffaele Scientific Institute 
in collaboration with the Institute ‘Villa Marelli’, Niguarda Ca´ Granda Hospital; NA: data not available; NMRL: National Mycobacterium 
Reference Laboratory; NRCM: National Reference Centre for Mycobacteria at Forschungszentrum Borstel; NTRL: National TB Reference 
Laboratory at the Latvian Infectology Centre; TBL: Tuberculosis Bacteriology Laboratory at the Infectious Diseases and Tuberculosis 
Hospital.
a  Respiratory samples: sputum, gastric aspirate, bronchoalveloar lavage, pleural fluid, other respiratory samples (e.g. nasopharyngeal 
aspirate). Non-respiratory samples: cerebrospinal fluid, lymph node, pus, other biopsy tissue, urine, other non-respiratory samples (e.g. 
pericardial fluid).
b  Data from 2011 only.
c  Does not include the 340 samples from Italy.
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routinely used GenoType MTBDRsl (Hain Lifescience, 
Germany) for rapid second-line DST. 
In 17 laboratories, the algorithms used to diagnose 
paediatric and adult TB did not differ; four laboratories 
reported the use of extra tests for children. In Latvia 
and Lithuania, for example, when there was a positive 
culture from a biopsy sample from a child GenoType 
MTBC (Hain Lifescience, Germany) was used to distin-
guish between MTB and M. bovis BCG. 
Routine laboratory data
Number and range of primary samples received
A total of 9,157 primary samples and 1,392 reference 
cultures were received from children across all six 
study sites within the five-year study period (Table 1). 
Of all primary samples, the vast majority (8,053/9,157, 
87.9%) were respiratory, including 4,974 sputum 
(61.8%), 1,467 BAL (18.2%), 1,232 GA (15.3%) and 298 
pleural fluid (3.7%) samples; 1,061 samples were 
non-respiratory, including 230 tissue biopsy sam-
ples other than LN (21.7%), 205 LN (19.3%), 182 urine 
(17.2%), 140 CSF (13.2%) and 118 pus (11.1%) (Figure).
In the Croatian, Latvian and Lithuanian sites, less than 
10% of all paediatric samples were non-respiratory 
(138/2,792, 4.9%; 222/2,401, 9.2%; 76/1,549, 4.9%, 
respectively), whereas in the UK site, this propor-
tion was higher, 490/2,140 (22.9%). The German site 
received more non-respiratory than respiratory pri-
mary samples (135/275, 49.1% and 129/275, 46.9%, 
respectively), with LN being the most common sample 
type (58/275, 21.1%) (Table 1, Figure).
Microscopy, culture and drug susceptibility testing
Most of the primary samples (8,176/9,157, 89.3%) were 
subjected to smear microscopy, resulting in a 3.3% 
(268/8,176) positivity rate (Table 2). More non-respira-
tory than respiratory samples were positive by micros-
copy (82/816, 10.0% vs 181/7,320, 2.5%, p<0.0001). 
Figure
Laboratory diagnosis of paediatric tuberculosis: type and percentage of paediatric primary samples received across five 
study sites, 2007–2011 (n=9,157)
CSF: cerebrospinal fluid; BAL: bronchoalveolar lavage; GA: gastric aspirate.
Data from the Italian laboratory were not included, since available data specified only that the samples were either respiratory or non- 















































Almost all (8,806/9,157, 96.2%) samples were cultured 
and a positive culture was obtained in 541 (6.1%) of the 
8,806 primary samples. Culture was more often posi-
tive from non-respiratory than from respiratory sam-
ples (142/1,015, 14.0% vs 392/7,749, 5.1%, p<0.0001 
for all positive cultures; 40/1,015, 3.9% vs 149/7,749, 
1.9%, p=0.0001 for MTB(C)-positive cultures) (Table 2).
Across all sites, the culture contamination rate (on 
solid and liquid media) was 169/8,806 (1.9%) (Table 2), 
ranging from 0/2,884 (0%) at the Croatian to 16/240 
(6.7%) at the German site.
Per-sample analysis showed that MTB(C) was detected 
in 236/8,851 (2.7%) of primary samples with the high-
est rates at the German and UK sites, 23/275 (8.4%) 
and 107/2,132 (5.0%), respectively (Table 3). The sam-
ple positivity rates for MTB(C) were significantly higher 
in pus (p=0.0005), LN (p<0.0001), CSF (p=0.002) and 
other tissue biopsy (p=0.002) samples compared 
with sputum samples. Among respiratory samples, 
MTB(C) was more commonly detected in GA samples 
than in sputum samples (43/1,231, 3.5% vs 89/4,684, 
1.9%, p=0.002). No statistically significant difference 
between MTB(C) detection rates in GA or BAL samples 
was observed. Per-patient analysis showed that MTB(C) 
was isolated in 156/5,156 (3.0%) of children (Table 4). 
MTB(C) was detected in 31/643 (4.8%) patients who 
submitted GA samples; of them, 21/31 patients sub-
mitted at least two GA samples. The first GA sample 
identified 16 positive patients, the second identified an 
additional four and the third, another positive patient.
Multidrug resistance (MDR), defined as resistance to 
at least rifampicin and isoniazid, was seen in 10/156 
(6.4%) of patients ranging from 0/23 and 0/4 at Croatian 
Table 2
Laboratory diagnosis of paediatric tuberculosis: tests performed on paediatric primary samples across the six study sites, 
2007–2011 (n=9,157)
Type of laboratory test Result




n (%) n (%)
Smear microscopy
All 7,320 (100) 816 (100) 8,176 (100)
Positive 181 (2.5) 82 (10.0) 268 (3.3)
Negative 7,139 (97.5) 734 (90.0) 7,908 (96.7)
Culturec
All 7,749 (100) 1,015 (100) 8,806 (100)
Positived 392 (5.1) 142 (14.0) 541 (6.1)
Positive: MTB(C)e 149 (1.9) 40 (3.9) 195 (2.2)
Positive: NTM 211 (2.7) 89 (8.8) 314 (3.6)
Negative 7,213 (93.1) 848 (83.5) 8,096 (91.9)
Contaminated 144 (1.8) 25 (2.5) 169 (1.9)
Direct rapid molecular 
identification of MTB(C) in 
primary samplesf
All 308 (100) 258 (100) 578 (100)
Positive for MTB(C)e 64 (20.8) 28 (10.8) 93 (16.1)
Negative 242 (78.6) 218 (84.5) 471 (81.5)
Indeterminate 2 (0.6) 12 (4.7) 14 (2.4)
Direct rapid molecular DST 
on primary samples
All 64 (100) 28 (100) 93 (100)
Rifampicin susceptible 59 (92.2) 26 (92.9) 85 (91.4)
Rifampicin resistant 4 (6.2) 2 (7.1) 7 (7.5)
Indeterminate 1 (1.6) 0 (0.0) 1 (1.1)
BCG: Bacillus Calmette–Guérin; DST: drug susceptibility testing; MTB(C): Mycobacterium tuberculosis complex; NTM: non-tuberculous 
mycobacteria.
a  Respiratory samples: sputum, gastric aspirate, bronchoalveloar lavage, pleural fluid, other respiratory samples (e.g. nasopharyngeal 
aspirate); non-respiratory samples: cerebrospinal fluid, lymph node, pus, other biopsy tissue, urine, other non-respiratory samples (e.g. 
pericardial fluid).
b  Including samples of unknown type.
c  Either Löwenstein–Jensen, Mycobacteria Growth Indicator Tube or other solid or liquid media. Only one positive culture result per sample 
was analysed.
d  32 of the 541 positive culture samples were either not further identified or were identified as M. bovis BCG.
e  M. bovis BCG not included. 
f  Used the following assays: Croatia: GeneXpert MTB/RIF, Amplified MTB Direct Test GenProbe; Germany: GeneXpert MTB/RIF, GenoType 
MTBDRplus, in-house test; Italy: GeneXpert MTB/RIF, INNO-LiPA; Latvia: GeneXpert MTB/RIF; Lithuania: GeneXpert MTB/RIF; United 
Kingdom: GeneXpert MTB/RIF, GenoType MTBDRplus, INNO-LiPA, IS6110 sequencing.
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Table 3
Laboratory diagnosis of paediatric tuberculosis: paediatric primary samples identified as MTB(C) across five study sites, 
2007–2011 (n=236)
Site
Number of samples identified as MTB(C)a/total number per sample type (%)




CIPH 6/1,402 (0.4) 20/694 (2.9) 9/516 (1.7) 1/20 (5.0) 0/0 (0.0) 0/19 (0.0) 0/3 (0.0) 1/138 (0.7) 37/2,792 (1.3)
Germanyb 
NRCM 1/29 (3.4) 9/53 (17.0) 5/39 (12.8) 2/58 (3.4) 0/1 (0.0) 1/13 (7.7) 2/35 (5.7) 3/47 (6.4) 46/2,397 (1.9)
Latvia 
NTRL 16/1,219 (1.3) 4/378 (1.1) 13/546 (2.4) 1/2 (50.0) 1/10 (10.0) 1/9 (11.1) 6/135 (4.4) 4/98 (4.1) 107/2,132 (5.0)
Lithuania 
TBL 13/1,099 (1.2) 0/17 (0.0) 2/54 (3.7) 4/40 (10.0) 0/1 (0.0) 0/6 (0.0) 1/1 (100) 3/37 (8.1) 23/1,255 (1.8)
United Kingdom 
NMRL 53/935 (5.7) 10/89 (11.2) 7/312 (2.2) 6/83 (7.2) 8/102 (7.8) 7/91 (7.7) 6/56 (10.7) 10/464 (2.2) 107/2,132 (5.0)
All sites 89/4,684 (1.9) 43/1,231 (3.5) 36/1,467 (2.5) 14/203 (6.9) 9/114 (7.9) 9/138 (6.5) 15/230 (6.5) 21/784 (2.7) 236/8,851 (2.7)
BAL: bronchoalveolar lavage; BCG: Bacillus Calmette–Guérin; CIPH: Croatian National Institute of Public Health; National Mycobacterium 
Reference Laboratory; CSF: cerebrospinal fluid; GA: gastric aspirate; MTB(C): Mycobacterium tuberculosis complex; NMRL: National 
Mycobacterium Reference Laboratory; NRCM: National Reference Centre for Mycobacteria at Forschungszentrum Borstel; NTRL: National 
TB Reference Laboratory at the Latvian Infectology Centre; TBL: Tuberculosis Bacteriology Laboratory at the Infectious Diseases and 
Tuberculosis Hospital.  
a  By isolation of MTB(C) culture or identification of MTB(C) nucleic acid in a sample. M. bovis BCG results are not included.
b  Data from 2011 only.
Table 4
Laboratory-confirmed paediatric casesa across the six study sites (with primary samples only), 2007–2011 (n=156)
Site
Type of primary sample Identification of MTB(C) Drug susceptibility testing 
Sputum Gastric aspirate n MTB(C)-positive 
patientsc/N patients 
(%)
n with MDR/ N MTB(C)- 
positive patientsc 
(%)
n samples/ N patients
(ratio)
n samples/ N patients
(ratio)
Croatia 
CIPH 1,402/1,006 (1.4) 694/391 (1.8) 23/1,681 (1.4) 0/23 (0.0)
Germanyb 
NRCM 29/21 (1.4) 53/22 (2.4) 7/152 (4.6) 1/7 (14.3)
Italyb 
HSR NA NA 4/200 (2.0) 0/4 (0.0)
Latvia 
NTRL 1,219/504 (2.4) 378/170 (2.2) 40/1,151 (3.5) 3/40 (7.5)
Lithuania 
TBL 1,385/774 (1.8) 18/13 (1.4) 17/886 (1.9) 3/17 (17.7)
United Kingdom 
NMRL 939/382 (2.5) 89/47 (1.9) 65/1,086 (6.0) 3/65 (4.6)
All sites 4,974/2,687 (1.9) 1,232/643 (1.9) 156/5,156 (3.0) 10/156 (6.4)
CIPH: Croatian National Institute of Public Health, National Mycobacterium Reference Laboratory; HSR: San Raffaele Scientific Institute 
in collaboration with the Institute ‘Villa Marelli’, NiguardaCa´ Granda Hospital;MDR: multidrug resistance (resistant to rifampicin and 
isoniazid); NA: data not available; NMRL: National Mycobacterium Reference Laboratory; MTB(C): Mycobacterium tuberculosis complex; 
NRCM: National Reference Centre for Mycobacteria at Forschungszentrum Borstel; NTRL: National TB Reference Laboratory at the Latvian 
Infectology Centre; TBL: Tuberculosis Bacteriology Laboratory at the Infectious Diseases and Tuberculosis Hospital.
a  By isolation of MTB(C) culture or identification of MTB(C) nucleic acid from any of the patient ś samples.
b  Data from 2011 only.
C  M. bovis BCG not included.
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and Italian sites to 3/17 of cases at the Lithuanian site 
(Table 4).
Rapid molecular test performance for Mycobacterium 
tuberculosis complex and drug-resistance detection
Routine use of NAAT was initiated in 1996 at the 
Croatian, in 1994 at the German and Italian, in 2010 
at the Latvian, in 2008 at the Lithuanian and in 1999 
at the UK sites. A variety of commercial and in-house 
assays were used on 578/9,157 (6.3%) of samples.
The bacteria in respiratory samples were more often 
directly identified as MTB(C) than those in non-res-
piratory samples (64/308, 20.8% vs 28/258, 10.9%, 
p=0.001). The rate of indeterminate results was higher 
among non-respiratory samples (12/258, 4.7% vs 
2/308, 0.6%, p=0.0024) (Table 2).
A total of 511 primary samples were tested by both 
molecular assay and culture for MTB(C) identifica-
tion. Compared with liquid or solid culture, a rapid 
molecular test – based on the pooled data analysis 
– had an overall (for all samples types) sensitivity of 
Table 5
Laboratory diagnosis of paediatric tuberculosis: performance of molecular assays compared with culture in detecting 
MTB(C) in primary samples across the six study sitesa, 2007–2011
Sample type 
and smear results




n/N % (95% CI) n/N % (95% CI) n/N % (95% CI) n/N % (95% CI) n/N % (95% CI)

























































































































































CI: confidence interval; MTB(C): Mycobacterium tuberculosis complex.
a  CIPH: Croatian National Institute of Public Health, National Mycobacterium Reference Laboratory; HSR: San Raffaele Scientific Institute 
in collaboration with the Institute ‘Villa Marelli’, NiguardaCa´ Granda Hospital; NMRL: National Mycobacterium Reference Laboratory; 
NRCM: National Reference Centre for Mycobacteria at Forschungszentrum Borstel; NTRL: National TB Reference Laboratory at the Latvian 
Infectology Centre; TBL: Tuberculosis Bacteriology Laboratory at the Infectious Diseases and Tuberculosis Hospital.
b  Number of true positives/number of true positives + number of false negatives. 
c  Number of true negatives/number of true negatives + number of false positives.
d  Number of true positives/number of true positives + number of false positives.
e  Number of true negatives/number of true negatives + number of false negatives.
f  Number of true positives + number of true negatives/total number of tested samples.
g  Number of smear negatives + number of smear positives + number with smear result unknown.
h  Number of respiratory samples + number of non-respiratory samples + number of samples of unknown type.
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57/72 (79.2%), specificity of 411/439 (93.6%), PPV of 
57/85 (67.1%), NPV of 411/426 (96.5%) and accuracy 
of 468/511 (91.6%) for MTB(C) detection (Table 5). 
The sensitivity of molecular tests for smear-positive 
samples vs smear-negative samples was significantly 
higher (42/46, 91.3% vs. 11/21, 52.4%, p=0.0006), 
while they were less specific (41/56, 73.2% vs 287/299, 
96.0%, p=0.0001). The lower specificity in the smear-
positive samples was due to 12 false-positive results 
at the UK site tested by INNO-LiPA Rif.TB (Innogenetics, 
Ghent, Belgium) and Xpert MTB/RIF, two at the German 
site tested by Xpert MTB/RIF and one at Croatian site 
tested by Xpert MTB/RIF.
The molecular tests detected MTB(C) in 48/54 (88.9%) 
of respiratory and 7/16 (43.8%) of non-respiratory sam-
ples (p=0.0004); the specificity was 224/236 (94.9%) 
and 177/192 (92.2%), respectively. For both respiratory 
and non-respiratory samples, the sensitivity was again 
higher for smear-positive than for smear-negative sam-
ples; however, the specificity was higher for smear-
negative samples for both groups of samples (Table 5).
Molecular assays produced 15/511 (2.9%) of false-
negative results and 28/511 (5.5%) of false-positive 
results for MTB(C) identification; discordant results 
were related to all types of samples. Mutations coding 
resistance to rifampicin were detected in 7/93 (7.5%) of 
all primary samples tested by rapid assays (Table 2). 
Molecular and phenotypic assays were fully concord-
ant with DST.
Non-tuberculous mycobacteria and Mycobacterium 
bovis BCG
Approximately half (989/1,903, 52.0%) of all posi-
tive isolates (grown from primary samples and those 
received as reference cultures) were identified as NTMs 
at the Croatian (43/94), German (54/90), Italian (26/50) 
and UK (862/1,564, 55.1%) sites. NTMs were less com-
mon at the Latvian (1/67) and Lithuanian (3/38) sites. 
A proportion of all positive isolates (224/1,903, 11.8%) 
were identified as M. bovis BCG.
NTMs were isolated at the highest rate from LN sam-
ples (27/203, 13.3%). NTMs were seen in 136/4,958 
(2.7%) of all paediatric patients, with M. abscessus as 
the most frequently identified.
Discussion
This large study reviewed the analysis of over 10,000 
samples tested across a number of European TB refer-
ence laboratories and showed the availability and use 
of all conventional and modern diagnostic techniques 
across these settings. Although the diagnostic algo-
rithms were similar across laboratories, approaches 
towards collecting paediatric non-respiratory samples 
differ between European sites, with very few samples 
other than sputum obtained from children in Latvia and 
Lithuania.
Because young children can rarely expectorate but 
instead swallow their sputum, aspiration of the gastric 
content is the best (and the least unpleasant) proce-
dure for obtaining a sputum sample suitable for fur-
ther diagnostics [4,5,19,24]. Our study showed that, 
compared with sputum samples, testing GA more often 
results in positive findings. Recent data by Fiebig et 
al. support this evidence [25]: they report widespread 
use of GA in Germany and a high (63%) yield of culture 
and NAAT in paediatric specimens, confirming that it is 
possible to reliably diagnose TB in children and disa-
greeing with the common notion of ‘difficulties’ in lab-
oratory confirmation of paediatric disease.
Our data suggest that collection of several GA samples 
might help identify further cases, in line with previ-
ously published data [5]. Larger studies are needed 
to assess the differences in diagnostic yield in serial 
samples.
Extrapulmonary samples also tested positive more fre-
quently than sputum samples did, placing emphasis 
on the usefulness of collecting non-respiratory mate-
rials, in line with some previously published results 
that showed a good performance of fine-needle aspi-
ration biopsy of LN in confirming TB [26]. Considering 
the observed small proportion of non-respiratory sam-
ples received at the Latvian and Lithuanian sites, it 
would seem reasonable to expect a low incidence of 
extrapulmonary TB there. However, crude comparison 
with World Health Organization (WHO) surveillance 
data for 2011 showed that while in Croatia, Germany, 
Italy and the UK extrapulmonary TB represented the 
minority of paediatric cases (15%, 17%, 19% and 37%, 
respectively), the majority of notified cases in Latvia 
and Lithuania were, in contrast, extrapulmonary (59% 
and 92%, respectively) [23], pointing towards predomi-
nantly non-laboratory based diagnosing. Within the 
framework of our study, infrequent collection of sam-
ples other than sputum might be explained by differ-
ences in the referral population, with a large number 
of asymptomatic children being screened for TB as 
part of contact tracing in medium-incidence settings, 
such as those of the participating Baltic countries [23]. 
Relatively low MTB(C)-positivity rates at the Latvian 
and Lithuanian sites also reflect this screening strat-
egy. There, a lower level of clinical suspicion might be 
the reason for not carrying out more invasive proce-
dures. Another explanation might be a more cautious 
attitude of eastern European physicians in Latvia and 
Lithuania in collecting GA or non-respiratory samples 
from children, related to the higher invasiveness of 
these procedures compared with sputum collection, 
and lack of confidence in the success of laboratory 
diagnosis. The rates of notified extrapulmonary TB 
across the EU/EEA vary between 4% and 48% (37.7% 
in children during 2002 to 2011), possibly reflecting the 
challenges and differences in diagnosis and confirming 
the urgent need for improvement [27,28].
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Analysis of the performance of the pooled molecular 
tests showed that the sensitivity was comparable to 
that reported for the Xpert MTB/RIF in children in other 
studies: 79.5% for sputum and GA in Vietnam, 90.0 and 
68.8% for sputum and GA samples in Zambia, 73.6% 
and 75.9% in South Africa using NPA and sputum sam-
ples, 54.7% in Tanzania [4,6,17-19]. The molecular tests 
were more sensitive in detecting MTB(C) in respiratory 
samples than in non-respiratory samples as previ-
ously described [17,29] which may be explained by the 
design of the molecular tests originally aimed to work 
in respiratory samples. We observed no differences in 
sensitivity and specificity for sputum, GA, or BAL sam-
ples, as previously observed [19].
The specificity was lower in smear-positive samples 
than in smear-negative samples. It might be an arte-
fact resulting from the pooling of different molecular 
methods or the low specificity of molecular tests for 
the DNA target or the use of an imperfect gold stand-
ard method. Although culture is the recognised cur-
rent gold standard for TB diagnosis, it still might be 
an imperfect comparator, possibly leading to failure to 
diagnose some cases [17].
Similar performance characteristics of INNO-LiPA Rif.
TB and Xpert MTB/RIF used for the diagnosis of TB in 
adults were reported in Italy and the UK [7,29]; how-
ever, these results were primarily evaluating a single 
rapid method (Xpert MTB/RIF) on a single type of sam-
ple.  High incidence of TB may explain the higher PPV 
observed in studies conducted outside Europe (100% 
for sputum and GA in Vietnam, 81.8% and 86.8% for 
sputum and GA samples respectively in Zambia, 92.8% 
and 89.7% in South Africa using NPA and sputum sam-
ples) [6,17-19], compared with our study.
Our study showed that NTMs were more frequently 
isolated from children than MTB(C). M. bovis BCG was 
frequently isolated in Latvia and Lithuania where BCG 
vaccination is a national policy. Our data showed that 
M. abscessus was the predominant NTM isolated from 
children while previously was the M. avium complex 
[30].
This study has several limitations. The analysis was 
based on subnational data, leading to possible selec-
tion bias and restriction of the geographical repre-
sentativeness of the study. A diagnostic bias resulting 
from more invasive samples being taken when there 
is a higher level of clinical suspicion may cause the 
higher positivity rates in non-respiratory samples. Two 
sites could provide 2011 data only. Small case numbers 
forced ’pooling’ of the NAAT results and our approach 
ignores the possible heterogeneity of results or differ-
ences in ROC curve of various tests. The retrospective 
laboratory-based approach did not allow the investi-
gators to obtain data on HIV status, clinical/radiologi-
cal findings and TB treatment. A more comprehensive 
assessment of the success of diagnosing TB in chil-
dren in Europe is needed. Ideally, new studies should 
be led by key organisations in the field of infectious 
diseases control and prevention, such as ECDC or 
WHO Regional Office for Europe, and result in effective 
recommendations.
As long as available evidence for paediatric TB diag-
nosis remains limited, however, this study is of public 
health importance as it reviewed routine laboratory 
work in a non-clinical trial context, allowing con-
clusions to be drawn based on real-life scenarios. 
Moreover, the study sites represent the largest labo-
ratories with reference functions. This work has also 
demonstrated that data from the ERLN-TB can be used 
to conduct operational research.
Despite the relative success in diagnosing TB when 
using non-respiratory or GA samples, the level of labo-
ratory confirmation in children remains low, resulting 
in treatment initiation based on a set of subjective 
parameters. TB treatment is long and antituberculo-
sis drugs have potential toxicity; therefore while it is 
important not to risk failing to diagnose TB, overdiag-
nosis may result in unnecessary psychological or phys-
ical stress for children [26]. With this in mind, a more 
intensive approach to obtaining paediatric samples, 
including samples other than sputum (in particular GA 
and non-respiratory samples), is advisable in order to 
increase the number of laboratory-confirmed cases 
and give physicians a much greater degree of confi-
dence when administering antituberculosis treatment. 
Additionally, a major effort is needed to optimise and 
evaluate molecular assays for analysis of GA or non-
respiratory samples, thus making the diagnosis of pae-
diatric TB more accurate.
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